Life Sciences Digital Summit
Many life sciences companies have experienced growth and are emboldened with stronger balance sheets from which to invest. 2022 will see significant investments in their portfolios, including next generation therapies and investments, to capitalize on their digital progress. With access to a myriad of tools to gather and analyze data, it’s time for life sciences companies to employ digitalization at scale. Everything from research and development (R&D), to commercial processes, to supply chain, to human resources is being reimagined, digitized, and transformed at a pace that we have not seen in years past.
Kelley Iuele
Speakers Include
Matic Meglic, MD, PhD, MBA
David Schlossman, MD, PhD, FACP, MSMI
Jeanine Brosch
Amy Brown
Can (John) Akgun, Ph.D.
Nick Brown
Mary Pat Saddler
Steffanie Bristol
Pei-Yun Sabrina Hsueh
Angela Holmes
Anthony Luttenberger
Rachael Malmberg
Cailin Kelly
Shree Seshan
Colin DiPaola
Igor Rudychev
Tim Smith
Wendy Zhang
Payal Jain
Vanitha Iyer Preston
Mohammad (Moh) Waqas
Amy Brown
Jose-Miguel Calderon Carpio
Leslie Pagel
Event Agenda
9:00 am - 9:15 am
Opening Remarks
Intro & Diamond Commentary
9:15 am - 9:45 am
Keynote
Leadership innovation - People, processes and technology
We often hear that the companies fully embracing digital transformation are capturing—and keeping—more customers and enjoying stronger profitability. Consider these figures from a McKinsey & Company study: organizations embracing digital are 23 times more likely to acquire new customers, six times more likely to retain current customers, and 19 times more likely to be profitable than companies that don't. So, how can leaders embrace the evolving role of technology and actually improve their organizations? How can we move our people from just talking goals and strategy… to actually transforming?
Joining us to discuss, Mary Pat Saddler, VP & Divisional CIO at Sandoz-Novartis.
9:45 am - 10:25 am
Panel Discussion
Leveraging AI & customer data to drive personalization & insights
In the life sciences field, leveraging AI and customer data has the potential to revolutionize the way organizations engage with customers. Clinical outcomes, price, and volume are no longer the sole consideration of value for HCPs and patients- they now expect brands to deliver relevant content and experiences on the right channels, at the right time, and with consent. Doing all of this requires not just data, but connected customer data. (Treasure Data). In addition, organizations are utilizing AI to analyze vast amounts of that customer data, including electronic medical records, clinical trial data, and patient feedback, to gain insights into customer behavior and preferences. Given the inherent complex nature of life sciences, we expect the leaders in the industry to transform business and achieve a competitive edge by adaption of AI (Cognizant).
During this session, the panelists will provide their insights on the opportunities and challenges of leveraging AI and customer data in the life sciences field, and how these technologies can be used to drive personalization and insights that benefit patients, healthcare providers, and the industry as a whole.
10:25 am - 10:35 am
10:25 am - 10:35 am
Insight Break
You can't innovate what you can't see - The role of connected assets in data driven innovation
The proliferation of smart connected assets throughout the patient journey has helped streamline the delivery of care. Often times, however, organizations miss out on opportunities due to lack of visibility. What data are we missing out on by having too narrow of a scope? How do we innovate what we aren't aware of? This briefing looks to shine a light on how visibility forms the basis of innovation, and how healthcare organizations need to harness visibility to unlock further innovation.
10:35 am - 11:25 am
Roundtables
Track 1: Doubling down on digital: Fully embracing digitalization
Sponsor:
A full 99% of life sciences organizations consider digital transformation to be a worthy endeavor, but just 12% are fully digital, according to new Salesforce research. With the rapid advancements in blockchain technology, data analytics, and artificial intelligence, companies in the life sciences sector are now looking to leverage these digital technologies to optimize their operations, enhance patient outcomes, and accelerate drug discovery and development (Gyan Consulting).
A scattershot approach to digital will no longer work for those who want to succeed in driving business value and delivering customer- and patient-centric experiences. Biopharma and MedTech companies are expected to evolve from just doing digital—to being digital.
For life sciences organizations to stay competitive in the digital healthcare industry, it's crucial that they move away from adopting digital technologies in isolated areas, and instead undertake comprehensive enterprise-wide digital transformation initiatives. Failure to do so may result in these companies being marginalized or constrained within the future digital healthcare ecosystem. (Gyan Consulting)
Questions to answer in this roundtable include:
• What is the difference between digital optimization and digital transformation in life sciences?
• Is modernizing processes/systems across the entire value chain and in core functions enough?
• What are the key challenges and risks in scaling up emerging technology in the life sciences industry when considering regulation, privacy and patient protection?
• With the life sciences industry being so heavily regulated, what can companies do to stay compliant while also working to modernize and digitize?
• With a multitude of systems and platforms being utilized across the industry, how can organizations work to improve interoperability so that data can easily be shared and exchanged between stakeholders?
• What can organizations do to modernize their legacy systems?
• How can companies work to centralize the experience of employees, customers, and stakeholders within a digital transformation strategy?
• What do you think the role of digital will be as we progress through the next decade?
Track 2: Adopting AI & ML at scale across the value chain to accelerate innovation
Sponsor:
Life sciences is primed for an innovation explosion, and AI and ML will be key to accelerating it. From research and development to clinical trials, along with health care delivery and patient care, cutting-edge technologies like artificial intelligence and machine learning are adding enormous value across the life sciences value chain.
And we may just be at the edge of the innovation boom. According to figures from Deloitte, about 80% of MedTech executives said the development of innovative products was a “top priority” for 2023; and 75% intend to focus more on their R&D investments. No surprise then, that Gartner says 51% of life sciences companies are increasing investments in AI/ML, to fuel all that innovation. According to Precedence Research, the global AI in life sciences market size is projected to worth around US$ 6.7 billion by 2030 and growing at a CAGR of 20% from 2022 to 2030.
Applying AI to big data in life sciences can help companies reshape business models and also enable life sciences companies to be more personalized and authentic in how they engage with health care professionals, patients, and other stakeholders. (Deloitte). The life sciences industry has likely only scratched the surface of the potential for technology to shape its future for the better, and AI and ML will no doubt continue to have a seat at the table.
Questions to answer in this roundtable include:
• What specific applications of AI and ML have the most potential to revolutionize the life sciences industry?
• How can AI/ ML be used to improve drug discovery and development processes? What about personalizing medicine and improving patient outcomes?
• How are you navigating the regulatory and compliance issues that come with the use of AI in the life sciences industry?
• How can organizations address the ethical concerns that come with the use of AI/ML?
• How can the life sciences industry gain the approval and trust of its stakeholders over the use of these technologies?
• How can life sciences organizations utilize AI/ ML to be more personalized and authentic in how they engage with HCPs, patients, and other stakeholders?
• What potential exists for AI and ML to transform the diagnosis and treatment of diseases, and what are the implications for healthcare providers and patients?
• What are some examples of successful applications of AI and ML in life sciences research, and what impact have these had on the field?
Track 3: The promise of personalization to enhance patient care
Personalization is improving consumer experiences everywhere, but in medicine, it has the potential to improve outcomes. We know that each person is different - not only in terms of their medical history, but also their personality, motivations, and values - and those differences can be amplified when it comes to making decisions about their health. By eschewing standard, “one-size-fits-all” treatments and approaches, the patient receives the right medicine or treatment at the right time, through the right channel.
Increasingly enabled by emerging technologies such as AI, innovations in this space are reshaping the therapeutic landscape and making way for the proactive management of disease. Ultimately, technology could be used to prevent people from becoming patients in the first place. Innovations such as drug impact monitoring, medical prescription agents, smart pharma hubs, and bioprinting enable the customization of drugs and the delivery of personalized treatments to each patient. (Gyan Consulting).
The digital channels that were created almost in a hurry during the early stages of the pandemic are not going to be competitive in a digital- first marketplace. New solutions have to be frictionless, but more importantly, they have to meet the changing appetites of customers driven largely by personalization. To ensure that companies create patient- centric products, digital will have to become a strategic priority. More importantly, IT will have to put the end user in mind when enabling and supporting cross functional teams to deliver outcomes that transform the patient health and experience.
Questions to answer in this roundtable include:
• What are some examples of personalization in life sciences, and how have they improved patient outcomes?
• What challenges and opportunities does personalized medicine present for healthcare providers and researchers in life sciences?
• Where is AI capability currently supporting personalized experiences, and what data and analysis practices will drive this?
• What ethical considerations must be taken into account when implementing personalized medicine in life sciences?
• How can personalized medicine impact healthcare costs and accessibility?
• What are the limitations of personalized medicine in life sciences, and how can they be addressed?
• What role do patient preferences and values play in personalized medicine, and how can they be incorporated into treatment decisions?
• How can personalized medicine contribute to the development of new treatments and therapies in life sciences?
11:30 am - 12:10 pm
11:30 am - 12:10 pm
Masterclass Breakouts
Unleashing the power of medical imaging in life sciences research and AI development
Medical images as complex data types provide powerful insights that can accelerate early discovery, innovation and the drug development process. However, managing and enabling computation with these large data types is challenging, especially in the life sciences R&D sector where a variety of medical imaging types (MR, PET, CT, etc) and associated data (clinical measures, reports, surveys, -omics, etc.) need to be orchestrated at scale to enable data-driven objectives. In this session, we will present Flywheel, the leading research data management and collaboration platform that is helping life sciences researchers capture greater value from their data assets to accelerate the development of AI and transform drug discovery timelines and processes.
12:10 pm - 12:40 pm
Headline Keynote
Impact digital experience through the power of listening
Listening directly to customer voices reveals both points of friction and areas of success along the patient journey, providing opportunities for quick iterations and key decision-making. This session will address strategies to revolutionize an omnichannel approach that is often overlooked by digital leaders as a renewable source of feedback and insights.
In this session you will:
• Explore key considerations in building a digital experience that will be viable long-term through a renewable source of patient feedback
• Better understand how conversations highlight bottlenecks and friction points so teams can create a high-quality patient experience
• Leverage a new data channel (conversations) to inform business strategy
• Take away actionable steps to build and sustain a patient-centric experience
9:00 am - 9:15 am
Opening Remarks
9:15 am - 9:45 am
Keynote
Chat with ChatGPT- Exploring the challenges and implications of AI
Join Jose Miguel Calderon- Carpio, GCSO Global Head of Technology at Johnson & Johnson, as he explores the implications, challenges, & opportunities of utilizing AI in the life sciences sector. In this session, attendees will gain an understanding, from Jose Miguel's perspective, on the potential that AI has in driving healthcare innovation, but also the risks associated with its use. What does the future look like in this space?
9:45 am - 10:25 am
Panel Discussion
Boosting engagement and enabling better patient journey processes
Superior patient experience boosts the reputation of life sciences organizations among patients, positively influences clinical outcomes, and has an indirect yet critical impact on life sciences’ bottom line. However, delivering a superior patient experience is anything but easy – it requires significant monetary and time investments, a patient-centric mindset, seamless coordination with care delivery teams, and the right digital means to enrich patient lives wherever possible (Indigene).
Additionally, IDC analysts predict that by 2025, 60% of life science firms will use health data platforms for physician engagement, along with patient journey processes. The connection of quality information that can be securely exchanged will support the patient and provider experience, and enable the growing demand for telemedicine and remote care.
Join this panel to hear from a variety of life science leaders on how organizations can overcome the barriers to patient centricity and ensure a better physician experience, and how that can ultimately lead to better patient journey processes and overall better outcomes.
10:25 am - 10:35 am
10:25 am - 10:35 am
Insight Break
Creating customer-centricity by listening at scale
An exploration into how AI is taking patient and customer conversations and turning them into a valuable and renewable source of insights for all business stakeholders to empower strategic decision-making, understand patient behaviors, and impact business outcomes.
10:40 am - 11:30 am
Roundtables
Track 1: Doubling down on digital: Fully embracing digitalization
Sponsor:
A full 99% of life sciences organizations consider digital transformation to be a worthy endeavor, but just 12% are fully digital, according to new Salesforce research. With the rapid advancements in blockchain technology, data analytics, and artificial intelligence, companies in the life sciences sector are now looking to leverage these digital technologies to optimize their operations, enhance patient outcomes, and accelerate drug discovery and development (Gyan Consulting).
A scattershot approach to digital will no longer work for those who want to succeed in driving business value and delivering customer- and patient-centric experiences. Biopharma and MedTech companies are expected to evolve from just doing digital—to being digital.
For life sciences organizations to stay competitive in the digital healthcare industry, it's crucial that they move away from adopting digital technologies in isolated areas, and instead undertake comprehensive enterprise-wide digital transformation initiatives. Failure to do so may result in these companies being marginalized or constrained within the future digital healthcare ecosystem. (Gyan Consulting)
Questions to answer in this roundtable include:
• What is the difference between digital optimization and digital transformation in life sciences?
• Is modernizing processes/systems across the entire value chain and in core functions enough?
• What are the key challenges and risks in scaling up emerging technology in the life sciences industry when considering regulation, privacy and patient protection?
• With the life sciences industry being so heavily regulated, what can companies do to stay compliant while also working to modernize and digitize?
• With a multitude of systems and platforms being utilized across the industry, how can organizations work to improve interoperability so that data can easily be shared and exchanged between stakeholders?
• What can organizations do to modernize their legacy systems?
• How can companies work to centralize the experience of employees, customers, and stakeholders within a digital transformation strategy?
• What do you think the role of digital will be as we progress through the next decade?
Track 2: Adopting AI & ML at scale across the value chain to accelerate innovation
Sponsor:
Life sciences is primed for an innovation explosion, and AI and ML will be key to accelerating it. From research and development to clinical trials, along with health care delivery and patient care, cutting-edge technologies like artificial intelligence and machine learning are adding enormous value across the life sciences value chain.
And we may just be at the edge of the innovation boom. According to figures from Deloitte, about 80% of MedTech executives said the development of innovative products was a “top priority” for 2023; and 75% intend to focus more on their R&D investments. No surprise then, that Gartner says 51% of life sciences companies are increasing investments in AI/ML, to fuel all that innovation. According to Precedence Research, the global AI in life sciences market size is projected to worth around US$ 6.7 billion by 2030 and growing at a CAGR of 20% from 2022 to 2030.
Applying AI to big data in life sciences can help companies reshape business models and also enable life sciences companies to be more personalized and authentic in how they engage with health care professionals, patients, and other stakeholders. (Deloitte). The life sciences industry has likely only scratched the surface of the potential for technology to shape its future for the better, and AI and ML will no doubt continue to have a seat at the table.
Questions to answer in this roundtable include:
• What specific applications of AI and ML have the most potential to revolutionize the life sciences industry?
• How can AI/ ML be used to improve drug discovery and development processes? What about personalizing medicine and improving patient outcomes?
• How are you navigating the regulatory and compliance issues that come with the use of AI in the life sciences industry?
• How can organizations address the ethical concerns that come with the use of AI/ML?
• How can the life sciences industry gain the approval and trust of its stakeholders over the use of these technologies?
• How can life sciences organizations utilize AI/ ML to be more personalized and authentic in how they engage with HCPs, patients, and other stakeholders?
• What potential exists for AI and ML to transform the diagnosis and treatment of diseases, and what are the implications for healthcare providers and patients?
• What are some examples of successful applications of AI and ML in life sciences research, and what impact have these had on the field?
Track 3: The promise of personalization to enhance patient care
Personalization is improving consumer experiences everywhere, but in medicine, it has the potential to improve outcomes. We know that each person is different - not only in terms of their medical history, but also their personality, motivations, and values - and those differences can be amplified when it comes to making decisions about their health. By eschewing standard, “one-size-fits-all” treatments and approaches, the patient receives the right medicine or treatment at the right time, through the right channel.
Increasingly enabled by emerging technologies such as AI, innovations in this space are reshaping the therapeutic landscape and making way for the proactive management of disease. Ultimately, technology could be used to prevent people from becoming patients in the first place. Innovations such as drug impact monitoring, medical prescription agents, smart pharma hubs, and bioprinting enable the customization of drugs and the delivery of personalized treatments to each patient. (Gyan Consulting).
The digital channels that were created almost in a hurry during the early stages of the pandemic are not going to be competitive in a digital- first marketplace. New solutions have to be frictionless, but more importantly, they have to meet the changing appetites of customers driven largely by personalization. To ensure that companies create patient- centric products, digital will have to become a strategic priority. More importantly, IT will have to put the end user in mind when enabling and supporting cross functional teams to deliver outcomes that transform the patient health and experience.
Questions to answer in this roundtable include:
• What are some examples of personalization in life sciences, and how have they improved patient outcomes?
• What challenges and opportunities does personalized medicine present for healthcare providers and researchers in life sciences?
• Where is AI capability currently supporting personalized experiences, and what data and analysis practices will drive this?
• What ethical considerations must be taken into account when implementing personalized medicine in life sciences?
• How can personalized medicine impact healthcare costs and accessibility?
• What are the limitations of personalized medicine in life sciences, and how can they be addressed?
• What role do patient preferences and values play in personalized medicine, and how can they be incorporated into treatment decisions?
• How can personalized medicine contribute to the development of new treatments and therapies in life sciences?
11:30 am - 12:00 pm
Innovation Exchange Keynote
Consent & preferences are key to unlocking meaningful relationships with your HCPs
In a world where healthcare professionals are suffering from digital fatigue, it is vital for companies to shift their approach in how they interact to ensure their messages are being seen. The first step in achieving this is through reimagining how you build trust. Using transparent language, putting the HCP in control of the relationship, and collecting zero and first party data on their exact preferences helps put you at a competitive advantage when forming impactful relationships that can break through the noise.
12:00 pm - 12:30 pm
12:00 pm - 12:30 pm
Closing Prime Keynote
Transforming the patient experience with digital health innovation
Everyone has a unique physiology - there is no one size fits all. What if we could measure the individual response of a patient to a therapy, and scale that for every patient, everywhere? The latest advances in digital health are bringing the ability to set a unique baseline to an individual, measure their response to treatment and adapt the care plan, and identify variances that allow us to proactively intervene at the first sign of clinical deterioration. These advances present us exciting new tools to increased therapy accessibility and personalization, getting more patients on the right therapy and helping them stay on treatment.
9:00 am - 9:15 am
Opening Remarks
9:15 am - 9:45 am
Keynote
Empowering data-driven decision making: The role of self-service analytics and data literacy in Life Sciences
Data literacy and self-service analytics are increasingly important in the life sciences field due to the volume and complexity of data being generated. In this session, join Shree Seshan, Sr. Director, Global Head of Data & Analytics at QuidelOrtho, as he discusses the role that these tools play in life sciences, how they empower data- driven decision making, and how they can ultimately improve patient outcomes and drive innovation.
9:45 am - 10:25 am
Panel Discussion
Innovation in clinical trials & drug development
Digital is improving how life sciences companies conduct trials, with virtual capabilities enabling better accessibility, even from a patient's home. By 2026, Gartner predicts over 60% of retail pharmacies will conduct clinical research. Wearables and the data they capture can further transform clinical trials. Similarly, drug development driven by data and AI is helping pharmaceutical companies speed drug discovery. In addition to digital innovation in this space, financial innovation plays a critical role in improving the efficiency and effectiveness of drug development and clinical trials, while also promoting greater patient access and reducing financial risks for investors and sponsors.
Where else can life science use technology in the product development process? Can ideas be validated and proven digitally before developing a minimum viable product (MVP) to take to market? Join this panel to hear from a variety of leaders in the life sciences sector as they dive into their experiences and insights in this space.
10:25 am - 10:35 am
Insight Break
10:40 am - 11:30 am
Roundtable Leaders Panel
11:40 am - 12:10 pm
Innovation Exchange Keynote
Unlock the power of your data: A high level discussion from CSL Behring, global head of data and analytics
Advancements in analytics are changing the landscape of life sciences. In a recent survey from Deloitte, 79% of life sciences executives said data analytics is critical for improving commercial effectiveness, and 57% said it is important for improving the customer experience. (Deloitte, 2021) So we know data is driving impactful business initiatives…but which data? Where do you focus?
Taking to this will be Wendy Zhang from CSL Behring with us on stage. Wendy is Global Head of Data & Analytics for Enterprise Functions, a data science leader with extensive experience in multiple industries including life sciences. Wendy is here to talk us through the power your organizations have - contained within your data.
12:10 pm - 12:40 pm
Closing Keynote
Why Attend
New connections
Build new connections with likeminded senior leaders
Business trends
Stay current with emerging business trends
Key takeaways
Downloadable and actionable takeaways
New partnerships
Accelerate key projects through meaningful new partnerships
Insights
De-risk new projects by gaining a broad range of insights
New technologies
Understand the impact new technology can make
An immersive
Digital Summit
interactive features including:
Audience Interaction
Engage with a virtual live audience just as you would at a physical event and create meaningful conversations.
Interactive Live Polling
Keep engaged through interactive live polling and gamification tools.
Direct connections
Ask your questions face-to-face with the speakers via our leading stage technology.
Relationship building
Build stronger connections with leading executives that you will take with you through your career
Thought Leadership
Content and insight from industry experts when it matters most
Intelligent interaction
Interactive quizzes gamify your experience
Related events
Have a question…
There is no cost associated with attending a GDS Summit. In return, we ask that all senior executives in participation attend for the full duration to ensure that all attendees get maximum value and insight from the interactive roundtables, live Q&As and breakout networking sessions.
Our digital summit portfolio is designed to bring together senior decision makers from large global businesses and innovative disruptor brands to drive industry forward through addressing business critical challenges collaboratively.
If you’re keen to build new connections with likeminded leaders, de-risk your projects through new insight and establish new partnerships that can accelerate your projects then apply to attend today.
Complete our form below if you’re interested in attending the summit and you meet our application criteria. A member of the GDS team will then reach out to run you through the programme and event format and discuss your participation.
On stage: co-host a panel discussion with a group of likeminded senior executives or host a solo keynote presentation. Both slots include elements of interactive audience Q&A
Off stage: become a roundtable moderator, leading the discussion with the same cohort of executives for the duration of the summit around a specific topic you’ve agreed to focus on during the roundtable session.
We can tailor a partnership package to help meet your business objectives. This might include brand awareness, driving traffic to your site or quality editorial content via exclusive interviews and Q&As with our executive audience. Enquire today for more information.